Non-allosteric inhibition of enolase 1 sensitizes triple-negative breast cancer for checkpoint inhibitors

被引：0
|
作者：
Tailor, Dhanir
Garcia-Marques, Fernando Jose
Bermudez, Abel
Li, Wenqi
Dheeraj, Arpit
Pitteri, Sharon J.
Malhotra, Sanjay V.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-5935
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5935
引用
收藏
页数：2
相关论文
共 50 条
  • [1] LAPATINIB SENSITIZES TRIPLE-NEGATIVE BREAST CANCER CELLS TO HDAC INHIBITORS
    Chen, Y-J.
    Chien, P-H.
    Huang, W-C.
    ANNALS OF ONCOLOGY, 2012, 23 : 34 - 34
  • [2] Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple-negative breast cancer to immune checkpoint inhibitors
    Chen, Xin-Yu
    Li, Bin
    Wang, Ye
    Jin, Juan
    Yang, Yu
    Huang, Lei-Huan
    Yang, Meng-Di
    Zhang, Jian
    Wang, Bi-Yun
    Shao, Zhi-Ming
    Ni, Ting
    Huang, Sheng-Lin
    Hu, Xi-Chun
    Tao, Zhong-Hua
    CANCER COMMUNICATIONS, 2023, 43 (09) : 1003 - 1026
  • [3] SCD-1 blockade sensitizes triple negative breast cancer to immune checkpoint inhibition.
    Vivekanandhan, Sneha
    Trynda, Justyna
    Marlow, Laura A.
    Shreeder, Barath
    Miller, James L.
    Kase, Adam M.
    Tan, Winston
    Knutson, Keith L.
    Copland, John A.
    CANCER RESEARCH, 2021, 81 (13)
  • [4] The Evolving Role of Immune Checkpoint Inhibitors in the Treatment of Triple-Negative Breast Cancer
    Steiner, Meghan
    Tan, Antoinette R.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (05) : 305 - 315
  • [5] Our experience with immune checkpoint inhibitors in triple-negative breast cancer patients
    Nishio, Minako
    Kojitani, Yoshiki
    Kitashiro, Saya
    Ishiduka, Yasunobu
    Otsuka, Tomoyuki
    Nishida, Naohiro
    Fujisawa, Fumie
    Sugimoto, Naotoshi
    Yagi, Toshinari
    Souma, Ai
    Kanaoka, Haruka
    Oyamayama, Yuri
    Taniguchi, Azusa
    Nakajima, Satomi
    Seto, Yukiko
    Kusama, Hiroki
    Watanabe, Noriyuki
    Matsui, Saki
    Nakayama, Takahiro
    Kudou, Toshihiro
    ANNALS OF ONCOLOGY, 2023, 34 : S1465 - S1465
  • [6] Window of opportunity trials with immune checkpoint inhibitors in triple-negative breast cancer
    Quintana, A.
    Saini, K. S.
    Vidal, L.
    Peg, V.
    Slebe, F.
    Loibl, S.
    Curigliano, G.
    Schmid, P.
    Cortes, J.
    ESMO OPEN, 2024, 9 (10)
  • [7] The emerging role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer
    Singh, Sima
    Numan, Arshid
    Maddiboyina, Balaji
    Arora, Saahil
    Riadi, Yassine
    Md, Shadab
    Alhakamy, Nabil A.
    Kesharwani, Prashant
    DRUG DISCOVERY TODAY, 2021, 26 (07) : 1721 - 1727
  • [8] Immune checkpoint inhibition in early-stage triple-negative breast cancer
    Varma, Revati
    Wright, Matthew
    Abraham, Jame
    Kruse, Megan
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (11) : 1225 - 1238
  • [9] HDAC inhibition modulates immune checkpoint pathway in triple-negative breast cancer
    Barberio, Manuela Terranova
    Thomas, Scott
    Ali, Niwa
    Pawlowska, Nela
    Park, Jeenah
    Rosenblum, Michael D.
    Budillon, Alfredo
    Munster, Pamela N.
    CANCER IMMUNOLOGY RESEARCH, 2018, 6 (09)
  • [10] Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition
    Chen, Xian
    Low, Kwang-Huei
    Alexander, Angela
    Jiang, Yufeng
    Karakas, Cansu
    Hess, Kenneth R.
    Carey, Jason P. W.
    Bui, Tuyen N.
    Vijayaraghavan, Smruthi
    Evans, Kurt W.
    Yi, Min
    Ellis, D. Christian
    Cheung, Kwok-Leung
    Ellis, Ian O.
    Fu, Siqing
    Meric-Bernstam, Funda
    Hunt, Kelly K.
    Keyomarsi, Khandan
    CLINICAL CANCER RESEARCH, 2018, 24 (24) : 6594 - 6610
12345